We next aimed to validate the most significant hits identified (FADS2 and ACSL4) using single guide RNA (sgRNA)-mediated editing in the NRAS wild-type expressing NB4 and MV411 and the NRAS-mutant KO52 (p.G13R) and TF1 (p.Q61P) AML cell lines. This evidence concerns the gene FADS2 and acute myeloid leukemia.